DAAs – direct acting antivirals
This page is part of Pocket ART, an easy guide to HIV treatment.
DAAS (direct acting antivirals) are new hepatitis C drugs that work directly against the hepatitis C virus (HCV).
HIV is now easy to treat and HCV can be cured (with DAAs). The meds work very well with low risk of side effects.
Since 2014, the following DAAs and fixed dose combinations have been approved – and more are in development. Links are to the EMA website for information on each DAA.
- daclatasvir 30, 60, and 90 mg (Daklinza)
- dasabuvir 250 mg (Exviera)
- sofosbuvir / ledispavir 400 mg / 90 mg (Harvoni)
- simepravir 150 mg (Olysio)
- sofosbuvir 400 mg (Sovaldi)
- ombitasvir / paritaprevir / ritonavir 2.5 mg / 75 mg / 50 mg (Viekirax)
- elbasvir / grazoprevir 50 mg /100 mg (Zepatier)
Even though HCV guidelines now only recommend oral DAA treatment, the high price of these medicines means that in many countries they are only available to people who have advanced liver damage.
More detailed information:
- DAAs: modern HCV treatment
- Who needs HCV treatment?
- How is HCV treated: which DAAs and for how long?
14 September 2017. Related: HIV & hepatitis C, Pocket ART.